Large-scale surveillance study of the safety and effectiveness of entecavir in Korean patients with chronic hepatitis B
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Entecavir (ETV) is effective and safe antiviral agent against hepatitis B virus (HBV) in clinical and real-world setting but, most studies were performed in single institute or have limitation in patient’s number. A large-scale nation-wide real-world surveillance study was carried out to investigate safety, efficacy and clinical effectiveness of ETV in Korean patients with chronic hepatitis B (CHB). Methods: Between 2006 and 2012, 3,444 patients were enrolled from 132 Korean institutions. For the safety assessment, investigators recorded the occurrence of observed and patient-reported adverse events (AEs), as well as laboratory abnormalities. Efficacy, which consisted of change in HBV DNA and alanine aminotransferase (ALT), was evaluated in patients who had received at least 16 weeks of ETV treatment. Overall clinical effectiveness, based on improvement of ALT, HBV DNA and patient’s symptoms, was evaluated by physicians. Results: Of the patients, 3,367 were evaluated for safety and 3,115 for efficacy and clinical effectiveness. Three hundred and eighty AEs were reported in 255 cases (7.57%), and 67 adverse drug reactions in 54 cases (1.6%). Serious AEs (SAE) were 19 events in nine cases (0.27%). Serious adverse drug reactions (SADR) were three events in two cases (0.06%), and unexpected SAE/SADR were three events in two cases (0.06%). Medical history and concomitant medications were factors inf luencing incidence rates of AEs. Overall clinical effectiveness rate was 96.53%, which was clinically assessed as marked improved or improved state. Conclusions: This study showed that ETV was well tolerated and clinically effective in Korean patients with CHB in a real-world nation-wide setting.
Abstract
Background/Aims: Entecavir (ETV) is effective and safe antiviral agent against hepatitis B virus (HBV) in clinical and real-world setting but, most studies were performed in single institute or have limitation in patient’s number. A large-scale nation-wide real-world surveillance study was carried out to investigate safety, efficacy and clinical effectiveness of ETV in Korean patients with chronic hepatitis B (CHB). Methods: Between 2006 and 2012, 3,444 patients were enrolled from 132 Korean institutions. For the safety assessment, investigators recorded the occurrence of observed and patient-reported adverse events (AEs), as well as laboratory abnormalities. Efficacy, which consisted of change in HBV DNA and alanine aminotransferase (ALT), was evaluated in patients who had received at least 16 weeks of ETV treatment. Overall clinical effectiveness, based on improvement of ALT, HBV DNA and patient’s symptoms, was evaluated by physicians. Results: Of the patients, 3,367 were evaluated for safety and 3,115 for efficacy and clinical effectiveness. Three hundred and eighty AEs were reported in 255 cases (7.57%), and 67 adverse drug reactions in 54 cases (1.6%). Serious AEs (SAE) were 19 events in nine cases (0.27%). Serious adverse drug reactions (SADR) were three events in two cases (0.06%), and unexpected SAE/SADR were three events in two cases (0.06%). Medical history and concomitant medications were factors inf luencing incidence rates of AEs. Overall clinical effectiveness rate was 96.53%, which was clinically assessed as marked improved or improved state. Conclusions: This study showed that ETV was well tolerated and clinically effective in Korean patients with CHB in a real-world nation-wide setting.
참고문헌 (20)
- [URL]
- Chae HB, "Current status of liver diseases in Korea: hepatitis B", Korean J Hepatol, 15(Suppl 6), pp.S13~S24 (2009)[DOI]
- "Korea National Health and Nutrition Examination Survey"[URL]
- Si Hyun Bae, "Hepatitis B Virus Genotype C Prevails Among Chronic Carriers of the Virus in Korea", Journal of Korean Medical Science, 20(5), pp.816~820 (2005), 대한의학회
- Kim H, "Molecular epidemiology of hepatitis B virus (HBV) genotypes and serotypes in patients with chronic HBV infection in Korea", Intervirology, 50, pp.52~57 (2007)[DOI]
- Korean Association for the Study of the Liver, "KASL clinical practice guidelines: management of chronic hepatitis B", Clin Mol Hepatol, 18, pp.109~162 (2012)[DOI]
- Pol S, "First-line treatment of chronic hepatitis B with entecavir or tenofovir in 'real-life' settings: from clinical trials to clinical practice", J Viral Hepat, 19, pp.377~386 (2012)[DOI]
- Chang TT, "A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B", N Engl J Med, 354, pp.1001~1010 (2006)[DOI]
- Lai CL, "Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B", N Engl J Med, 354, pp.1011~1020 (2006)[DOI]
- Sherman M, "Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B", Gastroenterology, 130, pp.2039~2049 (2006)[DOI]
- [URL]
- [URL]
- Hou JL, "Efficacy and safety of entecavir treatment in a heterogeneous CHB population from a 'real-world' clinical practice setting in China", J Viral Hepat, 20, pp.811~820 (2013)
- Mazzucco CE, "Entecavir for treatment of hepatitis B virus displays no in vitro mitochondrial toxicity or DNA polymerase gamma inhibition", Antimicrob Agents Chemother, 52, pp.598~605 (2008)[DOI]
- Liaw YF, "Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study", Hepatology, 54, pp.91~100 (2011)[DOI]
- Shim JH, "Efficacy of entecavir in treatment-naive patients with hepatitis B virus-related decompensated cirrhosis", J Hepatol, 52, pp.176~182 (2010)[DOI]
- Zoutendijk R, "Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naive patients with a partial virological response", Hepatology, 54, pp.443~451 (2011)[DOI]
- Manns MP, "Long-term safety and tolerability of entecavir in patients with chronic hepatitis B in the rollover study ETV-901", Expert Opin Drug Saf, 11, pp.361~368 (2012)[DOI]
- Tenney DJ, "20 Entecavir maintains a high genetic barrier to HBV resistance through 6 years in naive patients", J Hepatol, 50(Suppl 1), pp.S10~ (2009)
- Tenney DJ, "Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy", Hepatology, 49, pp.1503~1514 (2009)[DOI]